Incidence of heart failure after pacemaker implantation: a nationwide Danish Registry-based follow-up study.


Journal

European heart journal
ISSN: 1522-9645
Titre abrégé: Eur Heart J
Pays: England
ID NLM: 8006263

Informations de publication

Date de publication:
21 11 2019
Historique:
received: 23 11 2018
revised: 25 02 2019
accepted: 30 07 2019
pubmed: 11 9 2019
medline: 28 10 2020
entrez: 11 9 2019
Statut: ppublish

Résumé

The objective of the current study is to investigate the risk of heart failure (HF) after implantation of a pacemaker (PM) with a right ventricular pacing (RVP) lead in comparison to a matched cohort without a PM and factors associated with this risk. All patients without a known history of HF who had a PM implanted with an RVP lead between 2000 and 2014 (n = 27 704) were identified using Danish nationwide registries. An age- and gender-matched control cohort (matched 1:5, n = 138 520) without PM and HF was identified to compare the risk. Outcome was the cumulative incidence of HF including fatal HF within the first 2 years of PM implantation, with all-cause mortality and myocardial infarction (MI) as competing risks. Due to violation of proportional hazards, the follow-up period was divided into three time-intervals: <30 days, 30-180 days, and >180 days-2 years. The cumulative incidence of HF including fatal HF was observed in 2937 (10.6%) PM patients. Risks for the three time-intervals were <30 days [hazard ratio (HR) 5.98, 95% CI 5.19-6.90], 30-180 days (HR 1.84, 95% CI 1.71-1.98), and >180 days (HR 1.11, 95% CI 1.04-1.17). Among patients with a PM device, factors associated with increased risk of HF were male sex (HR 1.33, 95% CI 1.24-1.43), presence of chronic kidney disease (CKD) (HR 1.64, 95% CI 1.29-2.09), and prior MI (1.77, 95% 1.50-2.09). Pacemaker with an RVP lead is strongly associated with risk of HF specifically within the first 6 months. Patients with antecedent history of MI and CKD had substantially increased risk.

Identifiants

pubmed: 31504437
pii: 5554632
doi: 10.1093/eurheartj/ehz584
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

3641-3648

Commentaires et corrections

Type : CommentIn

Informations de copyright

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2019. For permissions, please email: journals.permissions@oup.com.

Auteurs

Bhupendar Tayal (B)

Department of Cardiology, Aalborg University Hospital, Hobrovej 18-22, Aalborg, Denmark.

Patricia Fruelund (P)

Department of Cardiology, Aalborg University Hospital, Hobrovej 18-22, Aalborg, Denmark.

Peter Sogaard (P)

Department of Cardiology, Aalborg University Hospital, Hobrovej 18-22, Aalborg, Denmark.

Sam Riahi (S)

Department of Cardiology, Aalborg University Hospital, Hobrovej 18-22, Aalborg, Denmark.

Christoffer Polcwiartek (C)

Department of Cardiology, Aalborg University Hospital, Hobrovej 18-22, Aalborg, Denmark.
Unit of Epidemiology and Biostatistics, Aalborg University Hospital, Hobrovej 18-22, Aalborg, Denmark.
Division of Cardiology, Duke University Medical Center, Durham, NC, USA.

Brett D Atwater (BD)

Division of Cardiology, Duke University Medical Center, Durham, NC, USA.

Gunnar Gislason (G)

Department of Medicine, Zealand University Hospital, Køge, Denmark.
Faculty of Health and Medical Science, University of Copenhagen, Copenhagen, Denmark.
The Danish Heart Foundation, Copenhagen, Denmark.
National Institute of Public Health, University of Southern Denmark, Denmark.

Niels Risum (N)

Department of Clinical Investigation and Cardiology, Nordsjaellands Hospital, Hillerød, Denmark.

Christian Torp-Pedersen (C)

Department of Cardiology, Aalborg University Hospital, Hobrovej 18-22, Aalborg, Denmark.
Department of Clinical Investigation and Cardiology, Nordsjaellands Hospital, Hillerød, Denmark.

Lars Kober (L)

Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.

Kristian Hay Kragholm (KH)

Department of Cardiology, Aalborg University Hospital, Hobrovej 18-22, Aalborg, Denmark.
Unit of Epidemiology and Biostatistics, Aalborg University Hospital, Hobrovej 18-22, Aalborg, Denmark.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH